Mobile

A randomized, double-blind, parallel group, placebo-controlled (with open-label active comparator arm), dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO072...

Update Il y a 4 ans
Reference: EUCTR2005-004216-70

A randomized, double-blind, parallel group, placebo-controlled (with open-label active comparator arm), dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO0728804 (dual PPAR alpha/gamma agonist) therapy when administered to patients with Type 2 diabetes mellitus

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To determine the dose(s) of RO0728804 which are efficacious in improving glycemic control, safe and tolerable in patients with Type 2 diabetes when administered orally, once daily for 16 weeks as compared to placebo.

Inclusion criteria

  • Type 2 diabetes mellitus

Links